SCHEMBL16768979

SCHEMBL16768979

CC1[C@@H](OCC2O[C@@H](C)C(OC(=O)c3ccccc3)[C@@H](C)[C@@H]2C)OC(COC(=O)c2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.42
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PTPN1 P18031 4/20 0.42
ALDH1A1 P00352 1/20 0.41
LGALS9 O00182 1/20 0.40
LGALS1 P09382 1/20 0.40
LGALS3 P17931 1/20 0.40
LGALS7; LGALS7B P47929 1/20 0.40
F11 P03951 2/20 0.39
PTPN2 P17706 1/20 0.38
PTPN11 Q06124 1/20 0.38
ELANE P08246 1/20 0.37
NT5E P21589 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 1/20 0.37
GAPDH P04406 1/20 0.37
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16768969 0.92 PTPN1 (0.47) USP2POLBMEN1KMT2APTPN1
SCHEMBL17773536 0.90 LGALS9 (0.42) USP2POLBMEN1KMT2APTPN1
SCHEMBL9880213 0.88 LMNA (0.43) USP2POLBMEN1KMT2APTPN1
SCHEMBL9880223 0.86 LGALS3 (0.38) USP2POLBMEN1KMT2APTPN1
SCHEMBL9880221 0.86 LGALS3 (0.46) LGALS9LGALS1LGALS3LGALS7; LGALS7BNT5E
SCHEMBL9880217 0.86 LGALS3 (0.38) USP2POLBMEN1KMT2APTPN1
SCHEMBL18067737 0.85 PTPN1 (0.53) USP2POLBMEN1KMT2APTPN1
SCHEMBL11981201 0.85 PTPN1 (0.53) USP2POLBMEN1KMT2APTPN1
SCHEMBL12292268 0.85 PTPN1 (0.53) USP2POLBMEN1KMT2APTPN1
SCHEMBL18654290 0.84 PTPN1 (0.51) USP2POLBMEN1KMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160144016-A1 SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE SYNGLYCO PHARMACEUTICALS, INC. (US) 2016-05-26 US disclosed
US-20150152129-A1 Synthetic Oligosaccharides for P. Aeruginosa Vaccine SYNGLYCO, INC. 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152129-A1 Synthetic Oligosaccharides for P. Aeruginosa Vaccine DDOST, FUT5, FUT6 USP2 1212/4885POLB 2699/4885MEN1 4766/4885
US-20160144016-A1 SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE DDOST, FUT5, FUT6 USP2 1212/4885POLB 2699/4885MEN1 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.